Javier Puente

5.1k total citations
164 papers, 1.5k citations indexed

About

Javier Puente is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Javier Puente has authored 164 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Pulmonary and Respiratory Medicine, 78 papers in Oncology and 48 papers in Surgery. Recurrent topics in Javier Puente's work include Bladder and Urothelial Cancer Treatments (41 papers), Prostate Cancer Treatment and Research (40 papers) and Renal cell carcinoma treatment (37 papers). Javier Puente is often cited by papers focused on Bladder and Urothelial Cancer Treatments (41 papers), Prostate Cancer Treatment and Research (40 papers) and Renal cell carcinoma treatment (37 papers). Javier Puente collaborates with scholars based in Spain, United States and United Kingdom. Javier Puente's co-authors include Eduardo Díaz‐Rubio, Miguel Martín, José Á. García-Sáenz, Javier Sastre, José Ángel Arranz, Daniel Castellano, Enrique Grande, Joaquim Bellmunt, Aranzazu González del Alba and Enrique Gallardo and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Javier Puente

147 papers receiving 1.5k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Javier Puente 786 639 426 424 320 164 1.5k
Pooja Ghatalia 517 0.7× 653 1.0× 330 0.8× 633 1.5× 257 0.8× 81 1.4k
Dingwei Ye 417 0.5× 621 1.0× 286 0.7× 502 1.2× 303 0.9× 88 1.2k
Brigitte Duclos 508 0.6× 769 1.2× 280 0.7× 627 1.5× 531 1.7× 52 1.6k
Antonella Palazzo 724 0.9× 495 0.8× 349 0.8× 311 0.7× 155 0.5× 68 1.2k
Vicente Guillém 1.2k 1.6× 642 1.0× 394 0.9× 374 0.9× 597 1.9× 52 2.0k
Shuanzeng Wei 504 0.6× 1.0k 1.6× 540 1.3× 908 2.1× 326 1.0× 73 2.1k
Myriam Decaussin‐Petrucci 307 0.4× 326 0.5× 399 0.9× 642 1.5× 462 1.4× 100 1.7k
R. J. Amato 588 0.7× 943 1.5× 442 1.0× 779 1.8× 816 2.5× 68 2.0k
Mototsugu Muramaki 424 0.5× 582 0.9× 235 0.6× 625 1.5× 429 1.3× 90 1.4k
Akira Ooki 617 0.8× 456 0.7× 303 0.7× 595 1.4× 331 1.0× 98 1.4k

Countries citing papers authored by Javier Puente

Since Specialization
Citations

This map shows the geographic impact of Javier Puente's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Javier Puente with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Javier Puente more than expected).

Fields of papers citing papers by Javier Puente

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Javier Puente. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Javier Puente. The network helps show where Javier Puente may publish in the future.

Co-authorship network of co-authors of Javier Puente

This figure shows the co-authorship network connecting the top 25 collaborators of Javier Puente. A scholar is included among the top collaborators of Javier Puente based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Javier Puente. Javier Puente is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Durán-Pacheco, Gonzalo, G. Scott Chandler, Vidya Maiya, et al.. (2024). Correlation of safety and efficacy of atezolizumab therapy across indications. Journal for ImmunoTherapy of Cancer. 12(11). e010158–e010158. 3 indexed citations
2.
Dean, David, Javier Puente, David J. Hoelzle, et al.. (2024). Virtual Surgical Planning for Point-of-Care Manufacturing. Procedia CIRP. 125. 90–95. 1 indexed citations
3.
Puente, Javier, D. Castellano Gauna, Ignacio Durán, et al.. (2024). Criteria and indicators to evaluate quality of care in genitourinary tumour boards. Clinical & Translational Oncology. 26(7). 1639–1646.
4.
Torre, M. de la, et al.. (2024). Molecularly Defined Renal Carcinomas. 8(1). 31–44.
5.
6.
Carles, Joan, R.A. Medina López, Javier Puente, et al.. (2023). Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis. Future Oncology. 19(12). 819–828. 1 indexed citations
7.
8.
9.
Naidoo, Jarushka, Gonzalo Durán-Pacheco, Vidya Maiya, et al.. (2023). 2032MO Correlation of safety and efficacy in atezolizumab therapy across indications. Annals of Oncology. 34. S1079–S1079. 1 indexed citations
10.
Motzer, Robert J., Saby George, Jaime R. Merchan, et al.. (2023). Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab. The Oncologist. 28(6). 501–509. 5 indexed citations
11.
Morales‐Barrera, Rafael, Guillermo Villacampa, Teresa Bonfill, et al.. (2023). Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment. Clinical & Translational Oncology. 25(12). 3556–3564. 1 indexed citations
12.
13.
Garrigós, Carmen, Javier Puente, B. Mellado González, et al.. (2022). Single-Nucleotide Polymorphism Associations with Efficacy and Toxicity in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel. Pharmacogenomics. 23(11). 627–638. 1 indexed citations
14.
15.
16.
Capdevila, Jaume, Federico Rojo, Antonio González-Martı́n, et al.. (2017). Molecular Profiling for Clinical Decision Making in Advanced Cancer: A Clinical Appraisal. 5(3). 77–85. 4 indexed citations
17.
18.
García-Donás, Jesús, Luis J. Leandro‐García, Aranzazu González del Alba, et al.. (2013). Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. Annals of Oncology. 24(9). 2409–2414. 62 indexed citations
19.
Garré, Pilar, Rosa M. Xicola, Brian J. Doyle, et al.. (2011). Analysis of the Oxidative Damage Repair Genes NUDT1 , OGG1 , and MUTYH in Patients from Mismatch Repair Proficient HNPCC Families (MSS-HNPCC). Clinical Cancer Research. 17(7). 1701–1712. 28 indexed citations
20.
Martín, Miguel & Javier Puente. (2007). Actualización del tratamiento adyuvante en cáncer de mama. SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pooja Ghatalia Breakdown of academic impact, for papers by Dingwei Ye Breakdown of academic impact, for papers by Brigitte Duclos Breakdown of academic impact, for papers by Antonella Palazzo Breakdown of academic impact, for papers by Vicente Guillém Breakdown of academic impact, for papers by Shuanzeng Wei Breakdown of academic impact, for papers by Myriam Decaussin‐Petrucci Breakdown of academic impact, for papers by R. J. Amato Breakdown of academic impact, for papers by Mototsugu Muramaki Breakdown of academic impact, for papers by Akira Ooki
Rankless by CCL
2026